A series of significant events have been reported around Quest Diagnostics (NYSE:DGX). The bio-tech firm has had a solid trading period, outperforming competitors on certain days although underperforming on others. A new deal in Digital Pathology was announced with the intent to accelerate AI and Digital Pathology Adoption in Cancer Diagnosis. Murali Balakumar was named as Senior Vice President and Chief Information and Digital Officer. Furthermore, Quest Diagnostics meets Q1 earnings predictions and raises the guidance for full year 2024. The bio-tech giant also announced the acquisition of certain assets of PathAI Diagnostics and Outreach Lab Services Business of Steward Health Care System. The company has also collaborated with Broad Clinical Labs and Instacart on separate initiatives and launched a Mobile Phlebotomy Service. With regards to its investors, they are pleased with a sturdy return of 62% return over the last five years. The analysis also covered the firm's financial performance and forecast, including the announcement of an increase in its dividend to $0.75. Overall, these developments demonstrate continued growth for Quest Diagnostics.
Quest Diagnostics DGX News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Fri, 10 May 2024 12:04:53 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -2
